Abstract
We investigated the effect of alpha-glucosidase inhibitor (acarbose) on lipid profiles in diabetic hemodialysis patients. Fourteen diabetic hemodialysis patients (6 males) received acarbose in doses of 150mg (n=10) or 300mg (n=4)/day for a period of 6 month. The patients' mean age was 61±2.2 years old, mean hemodialysis period was 8.8 years, and mean body mass index was 19.0±0.8. Efficacy of acarbose was assessed by blood glucose, immunoreactive insulin (IRI), HbA1c, total cholesterol (TC), HDL-cholesterol (HDL-C), triglyceride (TG), free fatty acid (FFA), apoproteins and lipoprotein (a) (Lp (a)). Blood glucose and IRI were measured at fasting and postprandial states. LDL-cholesterol (LDL-C) was calculated by the Friedwald formula. After 6 month, postprandial glucose (p<0.05) and IRI (p<0.05) were significantly reduced. However, there were no significant changes in fasting glucose and IRI, HbA1c. In lipid profiles, TC (p<0.01), HDL-C (p<0.05), LDL-C (p<0.01) were significantly elevated and Lp (a) (p<0.05) was significantly reduced. TG showed a tendency to decline, but the difference was not significant. In apoproteins, apoA1 (p<0.05), apoC2 (p<0.05), apoC3 (p<0.01) were significantly elevated and apoA2, apoB, apoE did not show any change. Administration of acarbose may correct low HDL-cholesterol and high Lp (a) state of diabetic hemodialysis patients.
